Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in IntangiblesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZNCF) Cash from Discontinued Operations (2016 - 2020)

Historic Cash from Discontinued Operations for Astrazeneca (AZNCF) over the last 4 years, with Q1 2020 value amounting to $139.0 million.

  • Astrazeneca's Cash from Discontinued Operations rose 13591.73% to $139.0 million in Q1 2020 from the same period last year, while for Mar 2020 it was $562.9 million, marking a year-over-year change of. This contributed to the annual value of $3.1 billion for FY2016, which is 2475.86% up from last year.
  • Astrazeneca's Cash from Discontinued Operations amounted to $139.0 million in Q1 2020, which was up 13591.73% from -$387.0 million recorded in Q1 2019.
  • Astrazeneca's Cash from Discontinued Operations' 5-year high stood at $869.2 million during Q1 2016, with a 5-year trough of -$387.0 million in Q1 2019.
  • In the last 3 years, Astrazeneca's Cash from Discontinued Operations had a median value of $139.0 million in 2020 and averaged $207.1 million.
  • In the last 5 years, Astrazeneca's Cash from Discontinued Operations surged by 159267.38% in 2016 and then skyrocketed by 13591.73% in 2020.
  • Quarter analysis of 3 years shows Astrazeneca's Cash from Discontinued Operations stood at $869.2 million in 2016, then crashed by 144.53% to -$387.0 million in 2019, then surged by 135.92% to $139.0 million in 2020.
  • Its Cash from Discontinued Operations was $139.0 million in Q1 2020, compared to -$387.0 million in Q1 2019 and $869.2 million in Q1 2016.